Faculty/Staff Detail

Zheng X et al., Shih WJ, Lin Y, Reuhl K et al, Rabson A, Conney AH. Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in immunodeficient mice. Cancer Res. 2004;64:1811-1820.

Lu SE, Lin Y, Shih WJ. Analyzing excessive no changes in clinical trials with clustered data. Biometrics 2004;257-267.

He W, Shih WJ. Use of joint models to assess treatment effects on disease markers and clinical events: the Proscar Long-Term Efficacy and Safety Study (PLESS). Clinical Trials 2004;1:362-367. 

Shih WJ, Ohman-Strickland P, Lin Y. Analysis of pilot and early phase studies with small samples sizes. Statistics in Medicine 2004;23:1827-1842. 

Lin Y, Shih WJ. Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics 2004;60:482-490.

Liao J, Lin Y, Selvanayagam ZE, Shih WJ. A mixed model for estimating the local false discovery rate in DNA microarray analysis. Bioinformatics 2004;20:2694-2701. 

Shih WJ, Quan H, Li G. Two-stage adaptive strategy for superiority and non-inferiority hypotheses in active controlled clinical trials. Stat. Med. 2004;23:2781-2798. 

Chen X et al., Lin Y, Shih WJ, Lubet R, Yang CS. Overexpression of 5-Lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of Zileuton and Celecoxib on carcinogenesis. Clinical Cancer Research 2004;10:6703-6709. 

Chin KV et al., Yang CS, Shih WJ. Application of expression genomics in drug development and genomic medicine. Drug Development Research 2004;62:124-133. 

Gao H, et al., Lin Y et al., Shih WJ et al., Shen MM, Abate-Shen C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 2004; 101: 17204-17209. 

Zheng X et al. Shih WJ, Lin Y, Chang R, Conney AH. Synergistic stimulatory effect of 12-O-tetradecanoylphorbol-13-acetate and capsaicin on macrophage differentiation in HL-60 and HL-525 human myeloid leukemia cells. International Journal of Oncology 2005;26:441-448. 

Goodin S et al., Shih WJ et al., Todd M, DiPaola RS. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J. Clin. Oncol. 2005;23:3352-3357. 

Li G, Shih WJ, Wang Y. Two-stage Adaptive Design for Clinical Trials With Survival Data. Journal of Biopharmaceutical Statistics 2005;15:707-718. 

Avila G, Zheng X et al., Shih WJ et al., Conney AH. Inhibitory Effect of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans-Retinoic Acid on the Growth of LNCaP Prostate Tumors in Immunodeficient Mice. The J. of Pharmacology and Exp. Therapeutics 2005;315:170-187. 

Rao K, Goodin S et al., Shih WJ, Lin Y et al., DiPaola RS. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer,  Prostate 2005;62(2):115-22. 

Chin KV et al., Wong YF, Lin Y, Shih WJ. Application of Expression Genomics for Predicting Treatment Response in Cancer, Ann NY Acad Sci. 2005;1058:186-195. 

Ju J et al., Lin Y, Ma J, Shih WJ, Carothers AM, Yang CS. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate. the major catechin in green tea. Cancer Res. 2005; 65(22):10623-10631. 

Wang HY et al., Lin Y et al., Shih WJ, Li H. A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome, Genome Research 2005;15(2):276-83. 

Zheng X et. al., Shih WJ, Lin Y, Lu SE, Rabson AB, Kong ANT, Conney AH. Effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) in Combination with Paclitaxel (Taxol) on Prostate Cancer LNCaP Cells Cultured In vitro or Grown as Xenograft Tumors in ImmunodeficientMice, Clin Cancer Res. 2006;12(11):3444-3451. 

Shih WJ. Commentary: Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison. Statistics in Medicine 2006; 25:933-941. 

Shih WJ, Lin Y. “Traditional and modified algorithm-based designs for phase I cancer clinical trials”. Statistical Methods for Dose-Finding Experiments. Ed. S. Chevret, Wiley & Sons, 2006:61-90. 

Greenawalt DM et al., Lin Y et al., Shih WJ, Lange K, Li H. Structure in a 2.5-Mb region on the long arm of chromosome 21 Strong correlation between meiotic crossovers and haplotype, Genome Res. 2006;16: 208-214. 

Michna L, Wagner GC, et al., Lin Y, Carlson K, Shih WJ, Conney AH, Lu YP. Inhibitory effects of voluntary running wheel exercise on UVB-induced skin carcinogenesis in SKH-1 mice, Carcinogenesis 2006;27(10):2108-2115. 

Shih WJ. Plan to be Flexible: A Commentary on adaptive designs, Biometrical Journal 2006; 48(4): 656-659. 

Li H, et al., Lin Y, et al., Shih WJ. “Microarray Analysis of a Large Number of Single Nucleotide Polymorphisms in Individual Human Spermatozoa”. The Genetics of Male Infertility. Ed. D. T. Carrell, NJ Humana Press, 2007:55-76. 

Lu YP, et al., Lin Y, Shih WJ, Conney AH.  Caffeine and caffeine sodium benzoate have a sunscreen effect, enhance UVB-induced apoptosis, and inhibit UVB-induced skin carcinogenesis in SKH-1 mice, Carcinogenesis, Carcinogenesis 2007;28(1):199-206. 

Wu Y, Shih WJ, Moore DF. Estimating a Survival Curve with Unlinked Entry and Failure Times. Statistics in Medicine 2007;26:3624-3638. 

Goodin S et al., Shih WJ, Gallo M, DiPaola R. Clinical and biological activity of soy protein powder supplementation in healthy male volunteers. Cancer Epidemiol Biomarkers Prev 2007;16(4): 829-33. 

Zheng X et al., Shih WJ, Lin Y et al., Conney AH. Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice. Clinical Cancer Research 2007;13(18): 5480-5487. 

Liu J et al., Harner J, Shih WJ. Is subcellular localization informative for modeling protein-protein interaction signal?  Research Letters in Signal Processing 2008; Article ID 365152, 5 pages, doi:10.1155/2008/365152. 

Zheng X et al., Shih WJ, Lin Y et al., Conney AH. Inhibitory effect of voluntary running wheel exercise on the growth of human pancreatic Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice, Oncol. Rep. 2008;19:1583-88. 

Wu Y, Shih WJ, Moore DF.  Elicitation of a Beta prior for Bayesian inference in clinical trials. Biometrical Journal  2008;50(2):212–223.

Saraiya B et al., Lin Y, Shih WJ, Aisner J, Strair RK, Rubin EH. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anti-Cancer Drugs 2008; 19:411-420. 

Lu-Yao G, Albertsen PC, Moore DF, Shih WJ, Lin, Y, DiPaola RS, Yao SL. Survival following primary androgen deprivation therapy among men with localized prostate cancer. J. American Medical Association 2008;300(2):173-181. 

Ouyang X et al., Lin Y, Shih WJ et al., Abate-Shen C. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer, Cancer Res. 2008;68(7):2132-2144. 

Wu Y and Shih WJ. Approaches to handling data when a phase II trial deviates from the pre-specified Simon’s two-stage design, Statistics in Medicine 2008;27(29):6190–6208. 

Shih WJ, Liu J. A simple method for screening binary models with large sample size and continuous predictor variables. Journal of Data Science 2009;7(4). 

Chu P-L, Lin Y, Shih WJ. Unifying CRM and EWOC designs for phase I cancer clinical trials. Journal of Statistical Planning and Inference 2009;139(3):1146-1163. 

Quan, H, Sun Q, Zhang J, Shih WJ. Comparisons between ITT and treatment emergent adverse event analyses. Statistics in Medicine 2008;27(26):5356-5376. 

Liu J, Chen L, Zhao H, Moore DF, Lin Y, Shih WJ. On calculating the probability of a set of orthologous sequences. Computational Biology and Chemistry: Advances and Applications 2009;2:37-48. 

Shih WJ. Two-stage sample size reassessment using perturbed unblinding. Statistics in Biopharmaceutical Research 2009;1: 74-80.